-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Piper Sandler Downgrades Fate Therapeutics to Neutral From Overweight, Adjusts Price Target to $12 From $71

Piper Sandler Downgrades Fate Therapeutics to Neutral From Overweight, Adjusts Price Target to $12 From $71

MT Newswires · 01/06/2023 02:54